All quotes are delayed by at least 15 minutes.
MarketGrader Top Down Analysis
Sector Analysis - LLY ranks 71 out of 580 stocks in the sector
Industry Analysis - LLY ranks 4 out of 28 stocks in the industry
| Eli Lilly & Co. |
Key Financials |
Relative to Peer Avg |
| Quarterly Revenue Growth |
N/A |
|
| Annual Revenue Growth |
1.48% |
|
| Quarterly Net Income Growth |
53.10% |
|
| Annual Net Income Growth |
8.48% |
|
| Quarterly Free Cash Flow Growth |
|
|
| Total Debt Relative to Total Capital |
28.17% |
|
| Operating Margin |
25.77% |
 Above |
| Return on Equity |
30.943% |
|
| Eli Lilly & Co. (LLY) Dilution Analysis |
| Latest EPS |
$1.42 |
EPS Gain From Buy-back |
$0.03 |
Top Competitors
| Company |
Revenue* |
Net Income* |
Rating |
Sentiment |
| JNJ |
17,508.00 |
3,497.00 |
Sign up to view |
| NVS |
14,091.01 |
2,410.83 |
Sign up to view |
| PFE |
13,500.00 |
2,742.00 |
Sign up to view |
| MRK |
10,693.00 |
1,593.00 |
Sign up to view |
| SNY |
10,607.90 |
1,321.54 |
Sign up to view |
| GSK |
9,969.35 |
1,480.54 |
Sign up to view |
| AZN |
6,219.75 |
984.83 |
Sign up to view |
| LLY |
5,602.00 |
1,548.00 |
Sign up to view |
| BMY |
3,831.00 |
609.00 |
Sign up to view |
| NVO |
3,527.20 |
1,055.88 |
Sign up to view |
*Revenue and Net Income figures are based on latest quarterly financials.
Sign up for complete Sentiment Analysis
Sign up for complete Fundamental Analysis
